Torcetrapib/atorvastatin combination therapy

References Papers of special note have been highlighted as: • of interest •• of considerable interest

• Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 PM:12485966 (2002).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110(2), 227–239 PM:15249516 (2004).
   PubMed Web of Science ®Google Scholar
• Bays HE. Extended-release niacin/lovastatin: The first combination product for dyslipidemia. Expert Rev. Cardiovasc.Ther.2(4), 485–501 (2004).
   PubMedGoogle Scholar
  •Review of the first combination lipid-altering drug in a single pill, highlighting the benefits of the complementary actions of niacin and statins on lipid levels.
   Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin survival study (4S). Lancet344(8934), 1383–1389 PM:7968073 (1994).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N. Engl. J. Med.333(20), 1301–1307 PM:7566020 (1995).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N. Engl. J. Med. 335(14), 1001–1009 PM:8801446 (1996).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 279(20), 1615–1622 PM:9613910 (1998).
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N. Engl. J. Med. 339(19), 1349–1357 PM:9841303 (1998).
   PubMed Web of Science ®Google Scholar
• MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7–22 PM:12114036 (2002).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346), 1623–1630 PM:12457784 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial – lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361(9364), 1149–1158 PM:12686036 (2003).
   PubMed Web of Science ®Google Scholar
• Bays H, Stein EA. Pharmacotherapy for dyslipidaemia – current therapies and future agents. Expert Opin. Pharmacother. 4(11), 1901–1938 PM:14596646 (2003).
   PubMed Web of Science ®Google Scholar
  •A comprehensive review of approved, and investigational lipid-altering drugs.
   Google Scholar
• Bays H. Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am. J. Cardiol.90(10B), 30K–43K PM:12467938 (2002).
   Google Scholar
• Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev. Cardiol. 6(4), 179–188 PM:14605511 (2003).
   PubMedGoogle Scholar
  •Review of the lipoprotein particle size effects of the combination extended-release niacin/lovastatin tablet compared to statins alone, emphasizing the complementary actions of these lipid-altering drugs.
   Google Scholar
• Castelli WP. Cholesterol and lipids in the risk of coronary artery disease – the Framingham heart study. Can. J. Cardiol.4(Suppl A), 5A–10A PM:3179802 (1988).
   PubMedGoogle Scholar
• Superko RH. Lipoprotein subclasses and atherosclerosis. Front. Biosci.6D355–D365 PM:11229880 (2001).
   PubMedGoogle Scholar
• Griffin BA. Lipoprotein atherogenicity: an overview of current mechanisms. Proc. Nutr. Soc. 58(1), 163–169 PM:10343354 (1999).
   PubMed Web of Science ®Google Scholar
• Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260(13), 1917–1921 PM:3418853 (1988).
   PubMed Web of Science ®Google Scholar
• Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276(11), 875–881 PM:8782636 (1996).
   PubMed Web of Science ®Google Scholar
• Lamarche B, St-Pierre AC, Ruel IL et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can. J. Cardiol.17(8), 859–865 PM:11521128 (2001).
   PubMed Web of Science ®Google Scholar
• Krauss RM, Stampfer MJ, Blauw GJ et al. A prospective study of LDL particle diameter and risk of myocardial infarction. Circulation 90(Pt. 2), I–460 (1994) (Abstract 2469).
   Google Scholar
• Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem. Soc. Trans. 31(Pt. 5), 1066–1069 PM:14505481 (2003).
   PubMed Web of Science ®Google Scholar
• Bays H, Abate N, Chandalia M. Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiol.1(1), 39–59 (2005).
   PubMedGoogle Scholar
  ••First paper to review ‘adiposopathy’, which is defined as pathological adipose tissue function that may be promoted and exacerbated by fat accumulation (adiposity) and sedentary lifestyle in genetically susceptible patients.
   Google Scholar
• Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109(7), 837–842 PM:14757686 (2004).
   PubMed Web of Science ®Google Scholar
• Griffin BA, Skinner ER, Maughan RJ. Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations. Atherosclerosis70(1–2), 165–169 PM:3355612 (1988).
   PubMedGoogle Scholar
• Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler. Thromb. 11(1), 174–182 PM:1987996 (1991).
   PubMed Web of Science ®Google Scholar
• Pascot A, Lemieux I, Prud'homme D et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J. Lipid Res. 42(12), 2007–2014 PM:11734573 (2001).
   PubMed Web of Science ®Google Scholar
• Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol. 23(10), 1724–1731 PM:12969988 (2003).
   PubMed Web of Science ®Google Scholar
• Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler. Thromb. Vasc. Biol.18(7), 1046–1053 PM:9672064 (1998).
   PubMed Web of Science ®Google Scholar
• Kwiterovich PO Jr. Lipoprotein heterogeneity: diagnostic and therapeutic implications. Am. J. Cardiol. 90(8A), 1i–10i PM:12419476 (2002).
   PubMedGoogle Scholar
• Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the theory of everything. Expert Rev. Cardiovasc. Ther. 3(3), 393–404 PM:15889967 (2005).
   PubMedGoogle Scholar
• Bays H. Adiposopathy: role of adipocyte factors in a new paradigm. Expert Rev. Cardiovasc. Ther. 3(2), 187–189 PM:15853591 (2005).
   PubMedGoogle Scholar
• Bays H, Shepherd J. Diabetes, metabolic syndrome and dyslipidemia. management strategies in diabetes 1–28 (2004).
   Google Scholar
• Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288(14), 1723–1727 PM:12365955 (2002).
   PubMed Web of Science ®Google Scholar
• Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinol. Metabol. Clin. N. Am.33(2), 333–350 PM:15158522 (2004).
   PubMed Web of Science ®Google Scholar
• Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 291(23), 2847–2850 PM:15199035 (2004).
   PubMed Web of Science ®Google Scholar
• Grundy SM. Small LDL. Atherogenic dyslipidemia, and the metabolic syndrome. Circulation 95(1), 1–4 PM:8994405 (1997).
   PubMed Web of Science ®Google Scholar
• DAIS Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis intervention study, a randomised study. Lancet357(9260), 905–910 PM:11289345 (2001).
   PubMed Web of Science ®Google Scholar
• Proctor SD, Pabla CK, Mamo JC. Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats. Atherosclerosis 149(2), 315–322 PM:10729381 (2000).
   PubMedGoogle Scholar
• Cabezas C. Postprandial lipaemia in familial combined hyperlipidemia. Biochem. Soc. Trans. 31(Pt. 5), 1090–1093 (2003).
   PubMedGoogle Scholar
• Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin. Pharmacother. 4(5), 779–790 PM:12740000 (2003).
   PubMed Web of Science ®Google Scholar
  •Review of a novel bile acid sequestrant polymer, with an emphasis on the complementary lipid effects when added to a statin.
   Google Scholar
• Bays H. Ezetimibe. Expert Opin. Investig. Drugs 11(11), 1587–1604 PM:12437505 (2002).
   PubMed Web of Science ®Google Scholar
  ••Review of a novel cholesterol absorption inhibitor, with an emphasis on the complementary lipid effects when added to a statin.
   Google Scholar
• Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther.26(11), 1758–1773 PM:15639688 (2004).
   PubMed Web of Science ®Google Scholar
  ••First published paper on the ezetimibe/simvastatin combination tablet, with an emphasis on the complementary lipid effects of this dual inhibition approach.
   Google Scholar
• Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1084–1091 PM:12423708 (11–15–2002).
   PubMedGoogle Scholar
• Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42(13), 1141–1160 PM:14531725 (2003).
   PubMed Web of Science ®Google Scholar
• McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J. Pediatr.143(1), 74–80 PM:12915827 (2003).
   PubMed Web of Science ®Google Scholar
• Recommended INN. International Nonproprietary Names for pharmaceutical substances (INN). WHO Drug Info. 17(2), 115–142 (2003).
   Google Scholar
• Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nature Rev. Drug Discov.4(3), 193–205 PM:15738977 (2005).
   PubMed Web of Science ®Google Scholar
• Clark RW, Sutfin TA, Ruggeri RB et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24(3), 490–497 PM:14739125 (2004).
   PubMed Web of Science ®Google Scholar
  ••Early study of torcetrapib.
   Google Scholar
• Cambien F. Genetics and coronary heart disease. Future Cardiol. 1(1), 17–27 (2005).
   PubMedGoogle Scholar
• Quinet E, Tall A, Ramakrishnan R, Rudel L. Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J. Clin. Invest. 87(5), 1559–1566 PM:2022728 (1991).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brewer HB Jr. et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23(2), 160–167 PM:12588754 (2003).
   PubMed Web of Science ®Google Scholar
  ••Discussion of CETP from one of the opinion leaders in the field.
   Google Scholar
• Brewer HB Jr, Santamarina-Fojo S. Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. Am. J. Cardiol.92(4B), 10K-16K PM:12948871 (2003).
   Google Scholar
  ••Discussion of HDL metabolism from one of the opinion leaders in the field.
   Google Scholar
• McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am. J. Cardiol.88(3), 270–274 PM:11472706 (2001).
   PubMed Web of Science ®Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350(15), 1505–1515 PM:15071125 (2004).
   PubMed Web of Science ®Google Scholar
  ••Early study of torcetrapib.
   Google Scholar
• Davidson M, McKenney J, Revkin JH, Shear DL. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor torcetrapib when administered with and without atorvastatin to subjects with a low level of high-density lipoprotein cholesterol. American College of Cardiology Poster abstract Annual Scientific Session, FL, USA, March 2005.
   Google Scholar
  ••Reports data concerning torcetrapib monotherapy and combination therapy with atorvastatin in some of the larger studies to date.
   Google Scholar
• Forrester JS, Makkar R, Shah PK. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation111(14), 1847–1854 PM:15824213 (2005).
   PubMedGoogle Scholar
• Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am. J. Med. 111(3), 185–191 PM:11530028 (2001).
   PubMed Web of Science ®Google Scholar
• Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. Am. J. Cardiol.87(5), 554–559 PM:11230838 (3–1-2001).
   PubMedGoogle Scholar
• McKenney J, Davidson M, Sasiela WJ, Tikkanen MJ, Bays HE. For the ATGOAL Investigators. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. Am. J. Cardiol. (2005) (In Press).
   Google Scholar
• Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am. J. Cardiol. 89(6), 667–671 PM:11897207 (2002).
   PubMed Web of Science ®Google Scholar
• Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol.81(5), 582–587 PM:9514454 (1998).
   PubMed Web of Science ®Google Scholar
• Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am. Heart J. 149(1), e1-PM:15660024 (2005).
   PubMedGoogle Scholar
• Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J. Am. Coll. Cardiol. 44(9), 1772–1779 PM:15519006 (2004).
   PubMed Web of Science ®Google Scholar
• Prisant LM. Clinical trials and lipid guidelines for type II diabetes. J. Clin. Pharmacol.44(4), 423–430 PM:15051751 (2004).
   PubMed Web of Science ®Google Scholar
• Pitt B, Waters D, Brown WV et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N. Engl. J. Med.341(2), 70–76 PM:10395630 (1999).
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435), 685–696 PM:15325833 (2004).
   PubMedGoogle Scholar
• Wanner C. Results of a randomized controlled trial with atorvastatin in dialyzed diabetic patients (“Dutsche Diabetes Bialyse Studie”). In: American Society of Nephrology's 37th Annual Meeting and Scientific Exposition. Basic and Clinical Science Symposia, MO, USA (2004).
   Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ et al. Design and baseline characteristics of the incremental decrease in end points through aggressive lipid lowering study. Am. J. Cardiol.94(6), 720–724 PM:15374773 (2004).
   PubMed Web of Science ®Google Scholar
• Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation106(13), 1690–1695 PM:12270864 (2002).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 PM:15007110 (2004).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan AS et al. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc. Dis.16(4), 389–395 PM:14584489 (2003).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352(14), 1425–1435 PM:15755765 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106(16), 2055–2060 PM:12379573 (2002).
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256), 577–581 PM:11558482 (2001).
   PubMed Web of Science ®Google Scholar
• Raggi P, Callister TQ, Davidson M, Welty FK et al. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am. Heart J. 141(5), 722–726 PM:11320358 (2001).
   PubMedGoogle Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352(1), 29–38 PM:15635110 (2005).
   PubMed Web of Science ®Google Scholar
• Deedwania PC. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). Am. Heart J. 148(6), 1053–1059 PM:15632893 (2004).
   PubMedGoogle Scholar
• Deedwania PC. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the study assessing goals in the elderly. Annual Scientific Session. Orlando American College of Cardiology, FL, USA November 2005.
   Google Scholar
• Mohler ER III, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108(12), 1481–1486 PM:12952839 (2003).
   PubMed Web of Science ®Google Scholar
• Stone PH, Lloyd-Jones DM, Johnstone M et al. Vascular basis for the treatment of myocardial ischemia study: trial design and baseline characteristics. Am. Heart J. 147(5), 875–882 PM:15131545 (2004).
   PubMedGoogle Scholar
• Gatto LM, Lyons MA, Brown AJ, Samman S. Trans fatty acids and cholesterol metabolism: mechanistic studies in rats and rabbits fed semipurified diets. Int. J. Food Sci. Nutr. 52(5), 435–441 PM:11517736 (2001).
   PubMedGoogle Scholar
• Watts GF. The yin and yang of cholesteryl ester transfer protein and atherosclerosis. Clin. Sci.(Lond)103(6), 595–597 PM:12444912 (2002).
   PubMedGoogle Scholar
  ••Discussion on the potential benefits and pitfalls of CETP inhibition.
   Google Scholar
• Sugano M, Makino N, Sawada S et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273(9), 5033–5036 PM:9478952 (1998).
   PubMed Web of Science ®Google Scholar
• Rittershaus CW, Miller DP, Thomas LJ et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol.20(9), 2106–2112 PM:10978256 (2000).
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406(6792), 203–207 PM:10910363 (2000).
   PubMed Web of Science ®Google Scholar
• Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin. Sci. (Lond) 103(6), 587–594 PM:12444911 (2002).
   PubMed Web of Science ®Google Scholar
• Inazu A, Brown ML, Hesler CB et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med.323(18), 1234–1238 PM:2215607 (11–1-1990).
   PubMed Web of Science ®Google Scholar
• Akita H, Chiba H, Tsuchihashi K et al. Cholesteryl ester transfer protein gene: two common mutations and their effect on plasma high-density lipoprotein cholesterol content. J. Clin. Endocrinol. Metab.79(6), 1615–1618 PM:7989465 (1994).
   PubMedGoogle Scholar
• Hirano K, Yamashita S, Nakajima N et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 17(6), 1053–1059 PM:9194754 (1997).
   PubMed Web of Science ®Google Scholar
• Barzilai N, Atzmon G, Schechter C et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290(15), 2030–2040 PM:14559957 (10–15–2003).
   PubMed Web of Science ®Google Scholar
• Moriyama Y, Okamura T, Inazu A et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 27(5 Pt. 1), 659–667 PM:9808796 (1998).
   PubMed Web of Science ®Google Scholar
• Curb JD, Abbott RD, Rodriguez BL. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J. Lipid Res. 45(5), 948–953 PM:14967821 (2004).
   PubMed Web of Science ®Google Scholar
• Zhong S, Sharp DS, Grove JS. Increased coronary heart disease in Japanese–American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97(12), 2917–2923 PM:8675707 (1996).
   PubMed Web of Science ®Google Scholar
• Hirano K, Yamashita S, Kuga Y et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15(11), 1849–1856 PM:7583564 (1995).
   PubMed Web of Science ®Google Scholar
• Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101(16), 1907–1912 PM:10779455 (2000).
   PubMedGoogle Scholar
• Barter, P. CETP and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20(9), 2029–2031 PM:10978244 (2000).
   PubMed Web of Science ®Google Scholar
• Isaacsohn JL, Troendle AJ, Orloff DG. Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 93(11A), 49C-52C PM:15178516 (2004).
   PubMedGoogle Scholar
• Bays H. Ezetimibe. Expert. Opin. Investig. Drugs 11(11), 1587–1604 PM:12437505 (2002).
   Google Scholar
• Bays HE, Dujovne CA, McGovern ME et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am. J. Cardiol. 91(6), 667–672 PM:12633795 (2003).
   PubMed Web of Science ®Google Scholar
• Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am. J. Cardiol. 89(6), 672–678 PM:11897208 (2002).
   PubMed Web of Science ®Google Scholar
• Bays HE. Commentary: Trial finds that simvastatin plus niacin is safe in people with coronary artery disease and low HDL cholesterol. Evidence-based Cardiovascular Med. 8, 173–176 (2004).
   Google Scholar
• Pike NB, Wise A. Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug? Curr. Opin. Investig. Drugs 5(3), 271–275 PM:15083592 (2004).
   PubMedGoogle Scholar
• Wise A, Foord SM, Fraser NJ, Barnes AA et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278(11), 9869–9874 PM:12522134 (2003).
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Kuivenhoven JA, Stalenhoef AF et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105(18), 2159–2165 PM:11994249 (2002).
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, de Grooth GJ, Kawamura H et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 95(9), 1085–1088 PM:15842977 (2005).
   PubMed Web of Science ®Google Scholar
• Avorn J. Torcetrapib and atorvastatin – should marketing drive the research agenda? N. Engl. J. Med. 352(25), 2573–2576 PM:15972861 (2005).
   PubMedGoogle Scholar
• Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364(6432), 73–75 PM:8316302 (1993).
   PubMed Web of Science ®Google Scholar
• Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19(4), 1105–1110 PM:10195942 (1999).
   PubMed Web of Science ®Google Scholar
• Brousseau ME, Diffenderfer MR, Millar JS et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25(5), 1057–1064 PM:15761191 (2005).
   PubMed Web of Science ®Google Scholar
  •Suggests that torcetrapib may not result in net excretion of cholesterol from the body, as assessed by fecal bile acid and sterols.
   Google Scholar
• Berenson Alex. Pfizer Plans12% Cost Cut As Sales Lag. New York Times, NY, USA (4–6–2005).
   Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374), 2005–2016 PM:12814710 (6–14–2003).
   PubMed Web of Science ®Google Scholar
• Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki heart study. Diabetes Care 15(7), 820–825 PM:1516498 (1992).
   PubMed Web of Science ®Google Scholar
• Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care 20(4), 614–620 PM:9096989 (1997).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Alexander CM, Cook TJ et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian simvastatin survival study. Arch. Intern. Med. 159(22), 2661–2667 PM:10597756 (12–13–1999).
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Mellies MJ, Sacks FM. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. The care investigators. Circulation 98(23), 2513–2519 PM:9843456 (1998).
   PubMed Web of Science ®Google Scholar
• Keech A, Colquhoun D, Best J et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasti.ng glucose: results from the LIPID trial. Diabetes Care 26(10), 2713–2721 PM:14514569 (2003).
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Feyter P, Macaya C et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287(24), 3215–3222 PM:12076217 (2002).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. 162(22), 2597–2604 PM:12456232 (2002).
   PubMed Web of Science ®Google Scholar
• Raggi P, Davidson M, Callister TQ et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 26, 112(4), 563-571 (2005) (Epub 2005).
   Google Scholar
• Lamarche B, Uffelman KD, Carpentier A et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J. Clin. Invest. 103(8), 1191–1199 (1999).
   Google Scholar
• Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am. J. Cardiol. 92(6), 670–676 (2003).
   Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr. Med. Res. Opin. 18(4), 220–228 (2002)
   Google Scholar
• Schartl M, Bocksch W, Koschyk DH et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 24, 104(4), 387–392 (2001).
   Google Scholar
• Okazaki S, Yokoyama T, Miyauchi K et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 110(9), 1061–1068 (2004).
   Google Scholar
• Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J. Lipid Res. 45(9), 1594–1607 (2004)
   Google Scholar